BIOTECH COMMUNICATIONS, FROM THE NUMBERS TO THE NARRATIVE.
The science is strong.
The audience is busy.
Making it look effortless is hard work.
WHY KOJENT
Inside the science.
Outside the echo chamber.
You know your science inside out. But the people you need to convince are scanning for reasons to believe, reasons to doubt and reasons to move on.
KOJENT helps life sciences companies make difficult science easier to enter, easier to care about and harder to forget — without killing what makes it serious, strange, difficult and important.
If they have to dive for the point, you've already lost them.
What needs to travel?
The thesis
Start with what makes it matter.
Your competition isn't just other biotechs. It's every reason to look away. We dig into the science and strategy to find the reason to look closer, then build your identity around it.
The deck
Pack the point; leave the rest.
We connect the science, numbers and milestones, anticipate the tough questions and establish with you what earns a slide, what belongs in the appendix and what needs another look.
The site
Give them a reason to stay.
We map what investors, partners and prospective hires need to know, where they might lose interest and how content, structure and design can turn curiosity into action.Â
The moment
Make the update worth a double take.
A milestone doesn't speak for itself. We dig into what changed, why it matters and what the evidence supports, so the news becomes part of a bigger story, not just another update.
The conversation
Keep it going without losing the point.
A good story has to hold up over time. We connect the corporate record, numbers and milestones to keep reports, updates and ongoing communications consistent, credible and worth following.
If they don't get it, they can't trust it, fund it, join it, or remember it.
Innosuisse grant application | Research | Strategy | Writing | Budget
Geneva, Switzerland · 2026
CHF 500,000
Awarded by Innosuisse for collaborative project with the Univeristy of Geneva.
Helix BioPharma Corp.
Vancouver, Canada · 2026
Confidential investor presentation | Scientific narrative | Roadmap | Financial modelling | Design
The proof
is in the work.
BEHIND THE WORK
Dr. Jessica Kourniaktis
I'm a strategic communicator who came to biotech by way of a doctorate in Cold War history from the University of Oxford. I've spent a decade working with life sciences companies, particularly Swiss biotech startups, from different sides of the table. That range of perspective makes my work possible.
I've been an academic, COO of Swiss biotech startups and a board member of a Swiss investment company. I've built and valued companies, worked on the investor side of due diligence and worked with agencies spanning specialist life sciences communications to consumer branding.
​
I bring a researcher's suspicion of easy answers, a non-scientist's willingness to ask the embarrassingly obvious questions, an eye for what sticks and an instinct for where the numbers or argument might come under fire. And I genuinely enjoy making things work, from the words and the structure to the design and the smallest details.
Through KOJENT, I get to bring all of that to the same table.
KOJENT works closely with a small number of life sciences companies at any one time. Boutique by design.
"What makes Jessica tremendously effective is her ability to understand the cross-implications of decisions in biotech (science, positioning, investor expectations, partnerships, and execution) and turn that complexity into clear, credible messaging."
Julien Grogg, PhD, MBA,
CEO of Release Therapeutics SA
Don't take
my word for it.Â
"Jessica understands our business and the realities of building a young start-up. Her contribution goes beyond delivering what we ask for: she thinks alongside us, offers fresh ideas and proactively helps us move things forward."
Glen George,
CEO and Co-Founder of aevX Bio SA
"Nearly 10 years on, I continue to work with her because I trust her judgment, value her capabilities, and would readily recommend her to founders or leadership teams looking for someone they can actually rely on at the intersection of strategy, communications and execution."
Thomas Mehrling, MD, PhD,
CEO of Helix BioPharma Corp.